Starlix (nateglinide)
- Region
- 🇪🇺 EU
- Active substance
- nateglinide
- Company
- Novartis Europharm Limited
- Status
- Withdrawn
- Therapeutic area
- Diabetes Mellitus, Type 2
- EU approval
- Tue 03 Apr 2001
- Application
- EMEA/H/C/000335
- ATC
- A10BX03
- Official record
- www.ema.europa.eu
Indication
Nateglinide is indicated for combination therapy with metformin in type-2 diabetic patients inadequately controlled despite a maximally tolerated dose of metformin alone.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Trazec Lapsed · Novartis Europharm Ltd.
Follow Starlix
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.